Unilife Corp (UNIS) 3.79 $UNIS
Health Care Equipment and Supplies Equities Technical Data - Medtronic, ResMed, Unilife, Edwards Lifesciences, and InspireMD
PR Newswire - Wed Apr 22, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
UNIS: 3.79 (-0.12), MDT: 78.01 (+0.93), RMD: 73.28 (+0.17), EW: 140.87 (+0.39), NSPR: 0.26 (+0.02)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Unilife elects Dr Richard Beckman as CMO
M2 - Thu Apr 09, 6:08AM CDT
Unilife (NASDAQ:UNIS)(ASX:UNS), a US based developer, manufacturer and commercial supplier of injectable drug delivery systems, announced on Wednesday that Richard L. Beckman, MD has been named as its senior vice president and chief medical officer.
UNIS: 3.79 (-0.12)
Unilife Appoints Dr. Richard Beckman as Chief Medical Officer
PR Newswire - Wed Apr 08, 8:18AM CDT
Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced the appointment of Richard L. Beckman, M.D. to the position of Senior Vice President and Chief Medical Officer. Dr. Beckman will also serve as the General Manager of Unilife's Ocular Delivery Systems business unit.
UNIS: 3.79 (-0.12)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.31 (-0.07), ZIOP: 10.88 (+0.03), UNIS: 3.79 (-0.12), FCSC: 4.01 (+0.01), XON: 44.53 (+0.36), MNKD: 4.90 (-0.09)
Unilife: Big Potential, Bigger Risks
Mark Chapman - at Seeking Alpha - Tue Mar 10, 9:50AM CDT
UNIS: 3.79 (-0.12), ATRS: 2.78 (unch)
Unilife (UNIS) Is Weak On High Volume Today
at The Street - Tue Mar 10, 9:02AM CDT
Trade-Ideas LLC identified Unilife (UNIS) as a weak on high relative volume candidate
UNIS: 3.79 (-0.12)
Short Interest Decreases By 10.6% For Unilife
MarketNewsVideo.com - Thu Feb 26, 3:22PM CST
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 2,592,526 share decrease in total short interest for Unilife Corp. , to 21,841,973, a decrease of 10.61% since 01/30/2015.
UNIS: 3.79 (-0.12)
Unilife's (UNIS) CEO Alan Shortall on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 7:58PM CST
UNIS: 3.79 (-0.12)
Unilife reports 2Q loss
Automated Insights - Mon Feb 09, 5:01PM CST
YORK, Pa. (AP) _ Unilife Corp. (UNIS) on Monday reported a loss of $19.4 million in its fiscal second quarter.
UNIS: 3.79 (-0.12)
Unilife (UNIS) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
UNIS: 3.79 (-0.12)
Unilife Corporation beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:13PM CST
UNIS: 3.79 (-0.12)
Unilife Corporation Announces Financial Results For Fiscal Year 2015 Second Quarter
PR Newswire - Mon Feb 09, 3:05PM CST
Unilife Corporation ("Unilife" or "Company"
(NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2014 ("the second quarter of Fiscal Year 2015", "2Q FY15" or "Current Quarter" .
UNIS: 3.79 (-0.12)
Unilife to Participate in the 2015 Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 9:08AM CST
Unilife Corporation ("Unilife" or "Company" (NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will participate in a fireside chat at the Leerink Global Healthcare Conference at 1:50 p.m. EST on Thursday, February 12, 2015. The conference will be held at The Waldorf Astoria Hotel in New York City, New York.
UNIS: 3.79 (-0.12)
Unilife Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Feb 04, 8:25AM CST
Unilife Corporation ("Unilife" (NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced the closing of its previously announced public offering in the United States of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,650,000 shares of common stock. As a result, Unilife issued a total of 12,650,000 shares in the offering at a public price of $3.75 per share.
UNIS: 3.79 (-0.12)
Unilife Corporation To Announce Financial Results For Second Quarter Fiscal 2015 On Monday, February 9, 2015
PR Newswire - Mon Feb 02, 7:00AM CST
Unilife Corporation ("Unilife" or "Company" (NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the second quarter fiscal 2015 ended December 31, 2014 after market trading ends on Monday, February 9, 2015.
UNIS: 3.79 (-0.12)
Unilife (UNIS) Stock Lower Today After Pricing Public Offering
at The Street - Fri Jan 30, 9:51AM CST
Shares of Unilife (UNIS) are down today on heavy trading volume after the company announced a public offering of stock at a price of $3.75 per share.
UNIS: 3.79 (-0.12)
Unilife initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 9:04AM CST
UNIS: 3.79 (-0.12)
Unilife Corporation Prices Underwritten Offering of Common Stock
PR Newswire - Fri Jan 30, 8:25AM CST
Unilife Corporation ("Unilife" (NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced the pricing of an underwritten public offering in the United States of 11,000,000 shares of its common stock to the public at a price of $3.75 per share. The net proceeds from the offering to Unilife are expected to be $38,792,500, after deducting underwriting discounts and commissions and estimated offering expenses payable by Unilife. In addition, Unilife has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,650,000 shares of its common stock. The offering is expected to close on February 4, 2015, subject to customary closing conditions.
UNIS: 3.79 (-0.12)
Unilife Corporation Announces Public Offering of Common Stock
PR Newswire - Thu Jan 29, 6:20PM CST
Unilife Corporation ("Unilife" (NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced it intends to offer and sell, subject to market conditions, shares of its common stock (which will be issued in the form of CHESS Depositary Interests to Australian investors) in an underwritten public offering in the United States and a private placement in Australia (together the "Offering" . Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the proposed Offering. Unilife expects to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of common stock sold in the Offering. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the final size or terms (including price) of the Offering.
UNIS: 3.79 (-0.12)
Health Care Equipment and Supplies Equities Technical Data - Medtronic, ResMed, Unilife, Edwards Lifesciences, and InspireMD
PR Newswire - Wed Apr 22, 7:30AM CDT
Editor Note: For more information about this release, please scroll to bottom.
UNIS: 3.79 (-0.12), MDT: 78.01 (+0.93), RMD: 73.28 (+0.17), EW: 140.87 (+0.39), NSPR: 0.26 (+0.02)
Auto-Injectors Market: Prefilled and Fillable Auto-injectors - Global Industry Analysis 2014 - 2020
M2 - Tue Apr 21, 5:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/25dl9q/autoinjectors) has announced the addition of the "Auto-Injectors Market (Product Types: Prefilled and Fillable Auto-injectors; Therapeutic Applications: Anaphylaxis, Multiple Sclerosis, Rheumatoid Arthritis and Others; Manufacturing Design: Standardized and Customized Auto-injectors) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global auto-injectors market has been segmented on the basis of product, therapeutic applications, and manufacturing design. Based on product type, the global auto-injectors market is classified into two major segments, namely prefilled auto-injectors and fillable auto-injectors. Based on therapeutic applications, the auto-injectors market is differentiated into four segments: anaphylaxis, multiple sclerosis, rheumatoid arthritis, and others. Depending upon the manufacturing design, the global auto-injectors market is categorized into two segments: standardized auto-injectors and customized auto-injectors. Market revenue in terms of USD million for the period between 2012 and 2020 along with the compound annual growth rate (CAGR %) from 2014 to 2020 are provided for all segments, considering 2013 as the base year. This report also includes recommendations that would help new market entrants in establishing presence and existing market players in expanding their global reach and market share in the auto-injectors market. The report concludes by profiling major players in the auto-injectors market. Company overview, financial overview, product portfolio, business strategy, and recent developments are provided for major market players in the company profile section. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Auto-injectors Market Overview Chapter 4 Global Auto-injectors Market, by Product Type Chapter 5 Global Auto-injectors Market, by Manufacturing Design Chapter 6 Global Auto-injectors Market, by Therapeutic Application Chapter 7 Global Auto-injectors Market, by Geography Chapter 8 Recommendations Chapter 9 Company Profiles - Antares Pharma, Inc. - Becton, Dickinson & Company - Biogen Idec - Mylan, Inc. - Novartis International AG - Pfizer, Inc. - Sanofi - Scandinavian Health Ltd (SHL) Group - Unilife Corporation - Ypsomed Holding AG For more information visit http://www.researchandmarkets.com/research/25...oinjectors
BIIB: 423.57 (+1.46), BDX: 144.33 (-1.24), UNIS: 3.79 (-0.12), PFE: 34.93 (+0.04), ATRS: 2.78 (unch), NVS: 103.45 (-0.62)
Unilife elects Dr Richard Beckman as CMO
M2 - Thu Apr 09, 6:08AM CDT
Unilife (NASDAQ:UNIS)(ASX:UNS), a US based developer, manufacturer and commercial supplier of injectable drug delivery systems, announced on Wednesday that Richard L. Beckman, MD has been named as its senior vice president and chief medical officer.
UNIS: 3.79 (-0.12)
Unilife Appoints Dr. Richard Beckman as Chief Medical Officer
PR Newswire - Wed Apr 08, 8:18AM CDT
Unilife Corporation (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced the appointment of Richard L. Beckman, M.D. to the position of Senior Vice President and Chief Medical Officer. Dr. Beckman will also serve as the General Manager of Unilife's Ocular Delivery Systems business unit.
UNIS: 3.79 (-0.12)
Griffin Securities' Keith Markey Thinks These 5 Stocks Have Substantial Upside
Life Sciences Report - Seeking Alpha - Fri Mar 13, 9:10AM CDT
For Keith Markey of Griffin Securities, the science is paramount. Without understanding the underlying basis for activity, safety and efficacy, there's just no betting on a biotech stock. Over the last 25 years, Markey has seen nearly every type of...
SYN: 2.31 (-0.07), ZIOP: 10.88 (+0.03), UNIS: 3.79 (-0.12), FCSC: 4.01 (+0.01), XON: 44.53 (+0.36), MNKD: 4.90 (-0.09)
Unilife: Big Potential, Bigger Risks
Mark Chapman - at Seeking Alpha - Tue Mar 10, 9:50AM CDT
UNIS: 3.79 (-0.12), ATRS: 2.78 (unch)
Unilife (UNIS) Is Weak On High Volume Today
at The Street - Tue Mar 10, 9:02AM CDT
Trade-Ideas LLC identified Unilife (UNIS) as a weak on high relative volume candidate
UNIS: 3.79 (-0.12)
Short Interest Decreases By 10.6% For Unilife
MarketNewsVideo.com - Thu Feb 26, 3:22PM CST
The most recent short interest data has been released by the NASDAQ for the 02/13/2015 settlement date, which shows a 2,592,526 share decrease in total short interest for Unilife Corp. , to 21,841,973, a decrease of 10.61% since 01/30/2015.
UNIS: 3.79 (-0.12)
Unilife's (UNIS) CEO Alan Shortall on Q2 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Feb 09, 7:58PM CST
UNIS: 3.79 (-0.12)
Unilife reports 2Q loss
Automated Insights - Mon Feb 09, 5:01PM CST
YORK, Pa. (AP) _ Unilife Corp. (UNIS) on Monday reported a loss of $19.4 million in its fiscal second quarter.
UNIS: 3.79 (-0.12)
Unilife (UNIS) Q2 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Feb 09, 3:25PM CST
UNIS: 3.79 (-0.12)
Unilife Corporation beats by $0.03, misses on revenue
Seeking Alpha - at Seeking Alpha - Mon Feb 09, 3:13PM CST
UNIS: 3.79 (-0.12)
Unilife Corporation Announces Financial Results For Fiscal Year 2015 Second Quarter
PR Newswire - Mon Feb 09, 3:05PM CST
Unilife Corporation ("Unilife" or "Company"
(NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2014 ("the second quarter of Fiscal Year 2015", "2Q FY15" or "Current Quarter" . UNIS: 3.79 (-0.12)
Unilife to Participate in the 2015 Leerink Global Healthcare Conference
PR Newswire - Fri Feb 06, 9:08AM CST
Unilife Corporation ("Unilife" or "Company"
(NASDAQ: UNIS, ASX: UNS), today announced that its Chairman and CEO, Alan Shortall will participate in a fireside chat at the Leerink Global Healthcare Conference at 1:50 p.m. EST on Thursday, February 12, 2015. The conference will be held at The Waldorf Astoria Hotel in New York City, New York. UNIS: 3.79 (-0.12)
Unilife Announces Closing of Underwritten Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares
PR Newswire - Wed Feb 04, 8:25AM CST
Unilife Corporation ("Unilife"
(NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced the closing of its previously announced public offering in the United States of common stock. Prior to the closing, the underwriters exercised in full their option to purchase an additional 1,650,000 shares of common stock. As a result, Unilife issued a total of 12,650,000 shares in the offering at a public price of $3.75 per share. UNIS: 3.79 (-0.12)
Unilife Corporation To Announce Financial Results For Second Quarter Fiscal 2015 On Monday, February 9, 2015
PR Newswire - Mon Feb 02, 7:00AM CST
Unilife Corporation ("Unilife" or "Company"
(NASDAQ: UNIS; ASX: UNS) announced today that it intends to release its financial results for the second quarter fiscal 2015 ended December 31, 2014 after market trading ends on Monday, February 9, 2015. UNIS: 3.79 (-0.12)
Unilife (UNIS) Stock Lower Today After Pricing Public Offering
at The Street - Fri Jan 30, 9:51AM CST
Shares of Unilife (UNIS) are down today on heavy trading volume after the company announced a public offering of stock at a price of $3.75 per share.
UNIS: 3.79 (-0.12)
Unilife initiates equity offering
Seeking Alpha - at Seeking Alpha - Fri Jan 30, 9:04AM CST
UNIS: 3.79 (-0.12)
Unilife Corporation Prices Underwritten Offering of Common Stock
PR Newswire - Fri Jan 30, 8:25AM CST
Unilife Corporation ("Unilife"
(NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced the pricing of an underwritten public offering in the United States of 11,000,000 shares of its common stock to the public at a price of $3.75 per share. The net proceeds from the offering to Unilife are expected to be $38,792,500, after deducting underwriting discounts and commissions and estimated offering expenses payable by Unilife. In addition, Unilife has granted the underwriters an option for a period of 30 days to purchase up to an additional 1,650,000 shares of its common stock. The offering is expected to close on February 4, 2015, subject to customary closing conditions. UNIS: 3.79 (-0.12)
Unilife Corporation Announces Public Offering of Common Stock
PR Newswire - Thu Jan 29, 6:20PM CST
Unilife Corporation ("Unilife"
(NASDAQ: UNIS, ASX: UNS), a leading developer and supplier of injectable drug delivery systems, today announced it intends to offer and sell, subject to market conditions, shares of its common stock (which will be issued in the form of CHESS Depositary Interests to Australian investors) in an underwritten public offering in the United States and a private placement in Australia (together the "Offering" . Jefferies LLC and Piper Jaffray & Co. are acting as joint book-running managers for the proposed Offering. Unilife expects to grant the underwriters an option for a period of 30 days to purchase up to an additional 15% of the shares of common stock sold in the Offering. The Offering is subject to market conditions, and there can be no assurance as to whether or when the Offering may be completed, or as to the final size or terms (including price) of the Offering. UNIS: 3.79 (-0.12)
